Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
July 02, 2024 16:05 ET
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Announces China’s NMPA Approval of Avatrombopag Maleate Tablets for the Treatment of CLD-Associated Thrombocytopenia
Spherix Global Insights Expands Therapeutic Area Coverage into Hematology
June 10, 2024 04:00 ET
|
Spherix Global Insights
EXTON, PA, June 10, 2024 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry,...
Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
November 06, 2023 13:07 ET
|
Sobi, Inc.
Health Canada Approves DOPTELET (avatrombopag) for Two Indications in Thrombocytopenia
Thrombocytopenia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 27+ Companies Working in the Domain
January 30, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Thrombocytopenia Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 27+ Companies Working in the Domain The...
Platelet and Plasma Market to exceed $6.5 billion by 2024: Global Market Insights, Inc.
July 25, 2018 05:00 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, July 25, 2018 (GLOBE NEWSWIRE) -- World Platelet and Plasma Market revenue is projected to surpass USD 6.5 billion by 2024; according to a new research report by Global...
Akers Biosciences Signs US Distribution Agreement with Diagnostica Stago
March 26, 2018 07:00 ET
|
Akers Biosciences Inc
THOROFARE, N.J., March 26, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, has...